Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L1CAM siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral, Intraperitoneal
01
Overview
L1CAM siRNA is an experimental RNA interference (RNAi) therapeutic modality designed to silence the expression of the L1 cell adhesion molecule (L1CAM), a transmembrane glycoprotein often overexpressed in various aggressive cancers. L1CAM is associated with epithelial-mesenchymal transition (EMT), tumor cell migration, invasion, and chemoresistance. By utilizing small interfering RNA (siRNA) sequences complementary to L1CAM mRNA, this approach triggers the RNA-induced silencing complex (RISC) to degrade the target transcript, thereby reducing L1CAM protein levels. Preclinical studies have explored various delivery systems, including liposomes and elastin-like polypeptide (ELP) nanoparticles, across indications such as ovarian, pancreatic, triple-negative breast, and prostate cancers.
- Other names
- L1 cell adhesion molecule siRNAL-1 cell adhesion molecule siRNAL 1 cell adhesion molecule siRNAsiL1CAMsiL-1CAMsiL 1CAML1 siRNAL-1 siRNAL 1 siRNA
02
Targets
L1CAM
Beyond the preview
Go deeper on L1CAM siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L1CAM siRNA.